7.46 (m, 2H), 7.34 (m, 3H), 5.38 (s, 1H), 3.72 (d, 2H), 3.60 (d, 2H),
was neutralized using a basic aqueous solution, then evaporated. The
residue was re-dissolved in methylene chloride, dried over Na2SO4 and
evaporated. The products are normally received in a quantitative yield.
3-(2-{4-[7-(5,5-Dimethyl-[1,3]dioxin-2-yl)-2,3-dihydro-thieno[3,4-b][1,4]
dioxin-5-trans-4-styryl-benzaldehyde (E-28): 1H NMR (300 MHz, CDCl3,
1.87 (t, 4H), 1.27 (s, 3H), 1.02 (m, 26H), 0.81 (m, 4H), 0.73 (s, 3H). 13
C
NMR (75 MHz, CDCl3, δppm): 153.3, 150.2, 140.6, 139.7, 137.8, 129.8,
126.1, 125.1, 121.2, 121.1, 120.7, 102.1, 77.7, 55.4, 40.1, 31.7, 30.2, 29.8,
29.1, 29.0, 23.5, 23.0, 22.5, 14.0. mp = 62 °C. High-resolution (HR) MS
(TOF ES+): m/z: 583.3144 (M+).
δ
ppm): 9.93 (s, 1H), 7.82 (d, 2H), 7.61 (d, 2H), 7.50 (d, 2H), 7.35
{4-[7-(5,5-Dimethyl-[1,3]dioxan-2-yl)-9,9-dioctyl-9H-fluoren-2-yl]-
benzyl}-phosphonic acid diethyl ester (19): 18 (1 g, 1.7 mmol), (4-boronic
acid – benzyl)-phosphonic acid diethyl ester[16] (0.5 g, 1.7 mmol),
15 mL of 2 M aqueous sodium bicarbonate and [P(Ph)3]2PdCl2 (0.4 mg,
0.00057 mmol) were added to 15 mL of toluene and the reaction mixture
was kept overnight at 100 °C. The organic phase was separated, dried
over Na2SO4 and evaporated. The product was purified over alumina
(methylene chloride) yielding 1 g (80% yield) of 19 in the form of a
yellow oil. 1H NMR (300 MHz, CDCl3, δppm): 7.72 (m, 2H), 7.62 (d, 2H),
7.53 (m, 3H), 7.45 (s, 1H), 7.40 (d, 2H), 5.47 (s, 1H), 4.06 (m, 4H), 3.83
(d, 2H), 3.68 (d, 2H), 3.24 (s, 1H), 3.19 (s, 1H), 1.99 (t, 4H), 1.35 (s,
3H), 1.26 (m, 20H), 0.89 (m, 10H), 0.83 (d, 4H), 0.81 (s, 3H), 0.79 (s,
2H). 13C NMR (75 MHz, CDCl3, δppm): 153.6, 152.8, 143.1, 142.1, 142.0,
141.9, 141.4, 139.2, 1323, 132.2, 132.0, 131.9, 129.1, 127.6, 126.8, 123.2,
122.6, 121.9, 121.4, 104.1, 79.6, 64.0, 57.0, 55.2, 42.1, 35.8, 34.7, 33.6,
33.4, 32.0, 31.8, 31.0, 30.9, 25.5, 24.9, 24.4, 24.3, 23.7, 18.2, 18.1, 15.9,
15.8. HRMS (TOF ES+): m/z: 731.4817 (M+H+).
General Wittig Reaction Procedure 1: 1.8 mmol of the phosphonium
salt were added to a solution of sodium ethoxide (82 mg, 3.6 mmol)
in ethanol then 2 mmol of the aldehyde were added. The reaction was
stirred for 1 h under nitrogen at room temperature. The solution was
then evaporated and the residue extracted with methylene chloride. The
organic layer was dried over Na2SO4 and evaporated. The product was
purified using chromatography.
(t, 2H), 7.30 (d, 2H), 7.05 (d, 1H). 13C NMR (75 MHz, CDCl3, δppm):
191.6, 143.4, 136.5, 135.6, 132.1, 130.2, 129.4, 128.7, 126.8. MS
(chemical ionization (CI)): m/z: 208.0 (M+).
Trans-4-(2-thiophen-2-yl-vinyl)-benzaldehyde
(E-29):
1H
NMR
(300 MHz, CDCl3, δppm): 9.98 (s, 1H), 7.80 (d, 2H), 7.52 (d, 2H), 7.35
(d,1H), 7.22 (s, 1H), 7.09 (d, 1H), 6.98 (m, 1H), 6.86 (d, 1H). 13C NMR
(75 MHz, CDCl3, δppm): 143.1, 142.1, 135.2, 130.3, 127.8, 127.6, 126.7,
126.6, 125.7, 125.1, 2.8. MS (TOF by affinity purification (AP+)): m/z:
215.1 (M+H+).
General Wittig Reaction Procedure 2: 2 mmol of the phosphonium
salt were added to a solution of t-BuOK (0.7 g, 6 mmol) in dry THF
(10 mL) and cooled to 0 °C. Then 2 mmol of the aldehyde were added.
The reaction was stirred for 1 h under nitrogen at room temperature. The
solution was then evaporated and the residue extracted with methylene
chloride. The organic layer was dried over Na2SO4 and evaporated. The
product was purified using chromatography.
3-(2-{4-[7-(5,5-Dimethyl-[1,3]dioxin-2-yl)-2,3-dihydro-thieno[3,4-b][1,4]
dioxin-5-yl]-phenyl}-vinyl)-9-hexyl-9H-carbazole (E-24): 1H NMR (500 MHz,
DMSO-d6, δppm): 8.39 (s, 1H), 8.18 (d, 1H), 7.65 (m, 7H), 7.40 (d, 2H),
7.23 (s, 1H), 7.21 (m, 1H), 5.67 (s, 1H), 4.39 (m, 4H), 4.29 (t, 2H), 3.61
(s, 4H), 1.76 (m, 2H), 1.22 (m, 6H), 1.16 (s, 3H), 0.82 (t, 3H), 0.73 (s,
3H). 13C NMR (125 MHz, CDCl3, δppm): 140.8, 140.2, 139.3, 137.3, 136.3,
131.6, 129.4, 128.5, 126.3, 125.7, 125.5, 124.4, 123.1, 122.8, 120.4, 118.9,
118.6, 117.4, 119.3, 108.8, 95.4, 77.7, 71.8, 64.7, 43.1, 31.5, 30.1, 29.6,
28.9, 26.9, 22.6, 14.1. mp = 103 °C. MS (TOF LD+): m/z: 607.29 (M+).
[4-(2-{4-[7-(5,5-Dimethyl-[1,3]dioxin-2-yl)-2,3-dihydro-thieno[3,4-b]
[1,4]dioxin-5-yl]-phenyl}-vinyl)-phenyl]-diphenyl-amine (E-25): 1H NMR
(500 MHz, CDCl3, δppm): 7.64 (d, 2H), 7.57 (d, 2H), 7.51 (d, 2H), 7.31
(t, 4H), 7.17 (s, 1H), 7.10 (s, 1H), 7.06 (m, 6H), 6.95 (d, 2H), 4.33 (d,
2H). 4.32 (d, 2H), 3.60 (s, 4H), 1.15 (s, 3H), 0.72 (s, 3H). 13C NMR (125
MHz, CDCl3, δppm): 149.3, 149.1, 141.2, 139.2, 137.8, 133.7, 133.4, 131.1,
129.7, 129.1, 128.4, 128.3, 128.2, 126.3, 125.4, 124.8, 119.2, 113.8, 97.2,
79.5, 66.5, 32.0, 24.7, 23.6. mp = 200 °C. MS (TOF MS ES+): m/z: 602.23
(M+H+).
Trans-4,4,5,5-tetramethyl-2-(4-styryl-phenyl)-[1,3]dioxolane
(E-20):
1H NMR (300 MHz, CDCl3, δppm): 7.51 (m, 6H), 7.36 (t, 2H), 7.26
(d, 1H), 7.12 (s, 2H), 5.99 (s, 1H), 1.34 (s, 6H), 1.29 (s, 6H). 13C NMR
(75 MHz, CDCl3, δppm): 139.1, 137.7, 137.3, 128.9, 128.7, 128.4, 127.6,
126.6, 126.5, 126.4, 82.7, 99.7, 24.3, 22.2. mp = 87 °C. MS (TOF LD+):
m/z: 308.2 (M+).
Trans-4,4,5,5-tetramethyl-2-[4-(2-thiophen-2-yl-vinyl)-phenyl]-[1,3]
dioxolanle (E-21): 1H NMR (300 MHz, CDCl3, δppm): 7.44 (s, 4H), 7.18
(d, 1H), 7.05 (d, 1H), 6.98 (t, 1H), 6.92 (s,1H), 6.87 (s, 1H), 5.95
(s, 1H), 1.31 (s, 6H), 1.26 (s, 6H). 13C NMR (75 MHz, CDCl3, δppm):
139.0, 128.0, 127.6, 126.6, 126.2, 124.4, 122.0, 99.7, 82.7, 24.3, 22.2.
mp = 94 °C. MS (TOF LD+): m/z: 314.3 (M+).
Trans-4,4,5,5-tetramethyl-2-(5-styryl-thiophen-2-yl)-[1,3]dioxolane (E-22):
1H NMR (300 MHz, CDCl3, δppm): 7.46 (d, 2H), 7.36 (t, 3H), 7.26 (s, 1H),
7.16 (d, 1H), 7.03 (d,1H), 6.90 (d, 1H), 6.15 (s, 1H), 1.46 (s 6H), 1.35 (s,
6H). 13C NMR (75 MHz, CDCl3, δppm): 143.6, 142.3, 136.9, 128.7, 128.5,
127.6, 126.7, 126.3, 125.7, 121.9, 96.7, 83.1, 24.3, 22.2. mp = 93 °C. MS
(TOF LD+): m/z: 314.1 (M+).
4,4,5,5-tetramethyl-2-{4-[2-(4-styryl-phenyl)-vinyl]-phenyl}-[1,3]dioxolane
(E,E-31): 1H NMR (500 MHz, CDCl3, δppm): 7.49 (m, 10H), 7.34 (t, 3H),
7.10 (s, 4H), 5.97 (s, 1H), 1.31 (s, 6H), 1.26 (s, 6H). 13C NMR
(125 MHz, CDCl3, δppm): 139.0, 137.2, 129.4, 129.0, 128.8, 128.3, 99.8,
82.5, 21.9. mp = 98 °C. MS (TOF LD+): m/z: 410.2 (M+).
4,4,5,5-tetramethyl-2-(4-{2-[4-(2-thiophen-2-yl-vinyl)-phenyl]-vinyl}-
phenyl)-[1,3]dioxolane (E,E-32): 1H NMR (500 MHz, CDCl3, δppm): 7.47
(m, 8H), 7.20 (d, 1H), 7.17 (d, 1H), 7.06 (s, 2H), 7.03 (d, 1H), 6.98
(m, 1H), 6.87 (d, 1H),5.97 (s, 1H), 1.31 (s, 6H), 1.26 (s, 6H). 13C NMR
(125 MHz, CDCl3, δppm): 142.9, 129.2, 128.7, 126.6, 126.0, 124.3, 121.6,
99.8, 82.6, 24.8, 22.1. MS (TOF LD+): m/z: 416.20 (M+).
3-(2-{4-[7-(5,5-Dimethyl-[1,3]dioxan-2-yl)-9,9-dioctyl-9H-fluorene-2-yl]-
phenyl}-vinyl)-9-hexyl-9H-carbazole (E-26): 1H NMR (500 MHz, CDCl3,
δppm): 8.27 (s, 1H), 8.02 (d, 1H), 7.72 (m, 7H), 7.62 (d,1H), 7.59
(s, 1H), 7.54 (d, 1H), 7.48 (d, 1H), 7.45 (s, 1H), 7.41 (m, 2H), 7.34
(s, 1H), 7.20 (s, 2H), 5.48 (s, 1H), 4.31 (t, 2H), 3.84 (d, 2H), 3.71 (d,
2H), 2.02 (t, 4H), 1.89(m, 2H), 1.36 (s, 3H), 1.18 (m, 33H), 0.88(m,
6H), 0.80(s, 3H). 13C NMR (125 MHz, CDCl3, δppm): 153.6, 152.8, 143.2,
142.7, 142.1, 142.0, 141.9, 141.5, 139.1, 138.7, 131.4, 130.1, 129.2, 128.4,
127.6, 127.5, 127.3, 126.8, 126.2, 125.0, 124.7, 123.1, 122.6, 122.2, 121.9,
121.5, 120.8, 120.5, 110.7, 104.2, 79.6, 57.0, 55.2, 45.0, 42.1, 33.6, 33.4,
32.1, 31.85, 31.05, 31.0, 30.8, 28.7, 25.5, 24.9, 24.4, 24.3, 23.7, 15.9, 15.8.
HRMS (TOF MS ES+): m/z: 856.6003 (M+H+).
[4-(2-{4-[7-(5,5-Dimethyl-[1,3]dioxan-2-yl)-9,9-dioctyl-9H-fluoren-2-yl]-
phenyl}-vinyl)-phenyl]-diphenylamine (E-27): 1H NMR (500 MHz, CDCl3,
δ
ppm): 7.77 (dd, 2H), 7.70 (d, 2H), 7.63 (d, 4H), 7.57 (d,1H), 7.50 (s,
1H), 7.46 (d, 2H), 7.30 (t, 4H), 7.16 (d, 4H), 7.14 (s, 1H), 7.12(d, 2H),
7.07 (t, 3H), 5.15 (s, 1H), 3.85 (d, 2H), 3.74 (d, 2H), 2.04 (t, 4H), 1.39
(s, 3H), 1.12 (m, 24H), 0.86 (m, 6H), 0.83 (s, 3H). 13C NMR (125 MHz,
CDCl3, δppm): 153.7, 152.8, 149.4, 149.2, 143.2, 142.3, 142.0, 141.4, 139.2,
138.4, 133.4, 131.1, 129.9, 129.2, 128.7, 128.6, 128.4, 127.5, 126.9, 126.4,
126.3, 125.4, 124.9, 123.1, 122.7, 122.0, 121.5, 104.2, 79.6, 57.1, 42.1,
33.6, 32.1, 31.8, 31.1, 31.0, 30.1, 25.6, 25.0, 24.4, 23.8, 15.9, 2.9. mp =
180 °C. MS (TOF ES+): m/z: 850.55 (M+H+).
4,4,5,5-tetramethyl-2-{5-[2-(5-styryl-thiophen-2-yl)-vinyl]-thiophen-
2-yl}-[1,3]dioxolane (E,E-33): 1H NMR (500 MHz, CDCl3, δppm): 7.37
(d, 2H), 7.27 (t, 2H), 7.18 (s, 1H), 7.16 (s, 1H), 7.05 (d, 1H), 7.00
(s, 1H), 6.94 (m, 5H), 6.17 (s, 1H), 1.37 (s, 6H), 1.33 (s, 6H). 13C NMR
(125 MHz, CDCl3, δppm): 143.1, 141.8, 136.8, 128.5, 127.1, 127.0, 126.9,
125.7, 121.7, 121.6, 96.4, 83.0, 24.2, 22.0. MS (TOF LD+): m/z: 422.
General Deprotection Procedure: Protected materials, such as 20–23,
were deprotected by heating their solution in a 1:2 mixture of 10%
HCl:THF to 60 °C under an inert atmosphere for 3 h. The solution
7-{4-[2-(4-Diphenylamino-phenyl)-vinyl]phenyl}-2,3-dihydro-
thieno[3,4-b][1,4]dioxin-5-carbaldehyde, (E-34): E-25 (0.3 g, 0.5 mmol)
was dissolved in 1:1 water/methylene chloride bi phasic mixture
(10 mL) and cooled to 0 °C. TFA (2 mL, 25 mmol) was added and
the resulting mixture was stirred at rt under nitrogen for 2 h. The
©
642 wileyonlinelibrary.com
2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Adv. Funct. Mater. 2011, 21, 634–643